Israeli remote patient monitoring company Biobeat has developed a device worn on the chest that measures blood pressure as the patient walks.

The disposable wearable and continuous ambulatory blood pressure monitoring (ABPM) chest-monitor includes an easy and intuitive patient self-set-up, requiring no assistance from a clinician or technician.

As blood pressure measurement has shown to be crucial in the early detection and prevention of clinical disorders, ABPM can act as a decisive indicator of patient health, tracking patient cardiac data continuously in real-life settings outside of the physician’s office to provide an accurate, holistic and unbiased view of patient health.

Claimed to be the only cuffless ABPM application in the world, in addition to retaining patient comfort while enabling the continuation of uninterrupted daily lifestyle, the disposable, sterile monitor is delivered directly to the patient’s home via courier.

“As healthcare continues its digital transformation, the use of ABPM technologies has become increasingly ubiquitous across the healthcare spectrum, and will continue its growth trajectory as we venture further into the post-Covid-19 era,” said Arik Ben Ishay, CEO of Biobeat. “Biobeat is excited to support this positive trend with our new wearable ABPM, giving providers a continuous and accurate real-life view into patient cardiac health, replacing antiquated cuff-based technology.”

The device measures diastolic and systolic blood pressure, as well as heart rate, mean arterial pressure, cardiac output and systemic vascular resistance. Measurements are accessible via the patient’s mobile phone via an app, and are readily available for physicians through an online report-analysis web application.

By using the wide range of vital signs measured by the device, the report enables health care providers to gain an understanding of the root cause of the issues identified and personalise medicine, allowing for more precise prescription and titration of medications and therapies.

The product is supported by a recently published peer-reviewed clinical study. The study, which compared Biobeat’s wearable wrist-monitoring device to a standard cuff-based ABPM device, found that Biobeat’s device had ABPM monitoring capabilities comparable with the standard cuff-based ABPM device. Findings also demonstrated standard cuff-based ABPM devices resulted in higher blood pressure values, likely due to a startle effect resulting from the inflating cuff, and that Biobeat’s wireless wrist monitor caused significantly less inconvenience compared with the cuff-based device.

Additionally, the study demonstrated a 24-hour bias of -1.1mmHg for both diastolic blood pressure (DBP) and systolic blood pressure (SBP), with a mean daytime bias of -1.9mmHg for DBP and SBP, and an even smaller night-time bias was determined.

“In addition to systolic and diastolic BP, Biobeat’s novel ABPM device measures cardiac output, stroke volume, heart rate, mean arterial pressure and systemic vascular resistance, providing a comprehensive clinical understanding of an individual’s health status,” said Arik Eisenkraft, chief medical officer of Biobeat. “This clinical study highlights the benefit of our device over commonly-used cuff-based ABPM devices, with a remarkable ease-of-use and lack of bias resulting from the mechanical effects of the inflating cuff.”

Biobeat provides an AI-powered wearable remote patient monitoring platform designed to elevate the standard of care for both short and long-term healthcare environments. Its disposable short-term chest-monitor and long-term wrist-monitor continuously provide accurate patient readings of 15 health parameters, including cuffless blood pressure, pulse rate, respiratory rate, blood oxygen saturation, stroke volume, cardiac output and one lead ECG. Aggregated patient health data are viewed by medical staff via Biobeat’s secure Hipaa and GDPR compliant cloud-based patient management platform, which uses an automated real-time early warning score that incorporates AI-based algorithms to provide alerts on patient health status and potential deterioration.

Biobeat’s wearable devices are FDA-cleared for cuffless non-invasive PPG-based blood pressure monitoring and are also CE Mark certified.

Founded in 2016, Biobeat is headquartered in Petah Tikva, Israel.